Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 4/20 | 0.58 |
| ▸ | NPC1 | O15118 | 3/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.58 |
| ▸ | PDE4A | P27815 | 2/20 | 0.47 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.47 |
| ▸ | PDE4C | Q08493 | 2/20 | 0.47 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 7/20 | 0.46 |
| ▸ | MEN1 | O00255 | 5/20 | 0.43 |
| ▸ | PDE5A | O76074 | 1/20 | 0.43 |
| ▸ | PDE1A | P54750 | 1/20 | 0.43 |
| ▸ | PDE1B | Q01064 | 1/20 | 0.43 |
| ▸ | PDE1C | Q14123 | 1/20 | 0.43 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.43 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 3/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9944196 | 0.84 | TAS1R3 (0.48) | RAB9ANPC1SMN1; SMN2PDE4APDE4B | |
| SCHEMBL9944161 | 0.83 | TAS1R3 (0.52) | RAB9ANPC1SMN1; SMN2PDE4APDE4B | |
| SCHEMBL9944187 | 0.81 | TAS1R3 (0.52) | RAB9ANPC1SMN1; SMN2PDE4APDE4B | |
| SCHEMBL9944182 | 0.81 | PDE4A (0.54) | RAB9ANPC1PDE4APDE4BPDE4C | |
| SCHEMBL9944181 | 0.80 | SMN1; SMN2 (0.62) | RAB9ANPC1SMN1; SMN2KMT2AMEN1 | |
| SCHEMBL9944176 | 0.80 | PDE4D (0.53) | RAB9ANPC1PDE4APDE4BPDE4C | |
| SCHEMBL9944162 | 0.79 | PDE4A (0.57) | RAB9ASMN1; SMN2PDE4APDE4BPDE4C | |
| SCHEMBL9944227 | 0.79 | PDE4A (0.51) | RAB9ANPC1SMN1; SMN2PDE4APDE4B | |
| SCHEMBL9944086 | 0.77 | PDE4A (0.49) | RAB9ANPC1PDE4APDE4BPDE4C | |
| SCHEMBL9944192 | 0.77 | PDE5A (0.46) | RAB9ANPC1PDE4APDE4BPDE4C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120149737-A1 | Therapeutic Aryl-Amido-Aryl Compounds and Their Use | KING'S COLLEGE LONDON (GB) | 2012-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120149737-A1 | Therapeutic Aryl-Amido-Aryl Compounds and Their Use | RARA, RARB, RARG | RAB9A 271/4885NPC1 277/4885SMN1; SMN2 696/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.